Chinese pharmaceutical firms’ US expansion plans to come up against brick wall of greater regulatory scrutiny

Source: Tech – South China Morning PostThe tightened regulation of deals involving biotechnology and biomanufacturing in the US could result in fewer transactions getting approvals, and could lead to Chinese companies seeking targets in Europe and Belt and Road Initiative countries.Read More

Geef een reactie

Het e-mailadres wordt niet gepubliceerd. Vereiste velden zijn gemarkeerd met *

Generated by Feedzy